Dianthus Therapeutics Inc. (DNTH) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Dianthus Therapeutics Inc. (DNTH) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (58/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (-26.0% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
How DNTH Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $2.0M | 44% | -8739.3% | -$162.3M | -$129.2M | -30.6% |
| FY 2024 | $6.2M | 44% | -1633.7% | -$85.0M | -$78.5M | -23.7% |
| FY 2023 | $2.8M | 44% | -1704.7% | -$43.5M | -$37.0M | -2.5% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring DNTH)
- ✓Live walkthrough of DNTH's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
DNTH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DNTH today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DNTH. Explore sector supply chains on /butterfly.
DNTH Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Dianthus Therapeutics Inc. (DNTH)?
In FY 2025 (10-K), DNTH converted $2.0M of revenue into a 44% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).